BioSpace News Archive

The cost of providing quality healthcare is rising and this issue is faced by even the developed countries of the West. Hence providing efficient, quality and cost-effective healthcare is a priority for all.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, presented positive 48-week data from its global phase III ATLAS-2M study of the investigational, long-acting, injectable, 2-drug regimen (2DR) of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine for the treatment of HIV.

Partnership includes Seattle Foundation, United Way of King County, King County, City of Seattle, Alaska Airlines, Amazon, Microsoft, and The Starbucks Foundation

Nanotechnology is expected to potentially transform healthcare industry, especially in the medical devices field in the coming years. The global market for Nano healthcare technology for medical equipment has been witnessing a rising growth path since 2012. Till 2016, this market has seen gradual growth, however, during the 2017-2022 period this market is expected to witness a robust growth rate.

Healthcare quality management aims to improve the effectiveness of treatments and increase the satisfaction of the patients with the services they are being provided with. For this purpose, various laws have been enacted by the governments all across the world so that the interests of the patients are protected.

Secure messaging in healthcare is set to become a billion-dollar market by 2029, as indicated by a new research report of Persistence Market Research (PMR).

As the world comes together to fight coronavirus, Canadians with life-threatening rare and common diseases will march on Parliament Hill to ask for the same support in the ‘Fight for Our Lives’

Vizient, Inc. announces it will participate in Food and Drug Administration /Federal Trade Commission Workshop on a Competitive Marketplace for Biosimilars in Silver Spring, Maryland.

REGENXBIO Inc. announced it will present and hold a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 11, 2020, at 2:35 p.m. ET.

Phase 3 trial did not meet primary endpoint of progression-free survival in patients not eligible for transplant